- Home
- TCMD vs BDTX Comparison
TCMD vs BDTX Comparison
Compare TCMD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | BDTX |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.5M | 171.9M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TCMD | BDTX |
|---|---|---|
| Price | $27.78 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $36.00 | $9.67 |
| AVG Volume (30 Days) | 229.8K | ★ 2.2M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.14 | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $9.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.42 | $1.60 |
| 52 Week High | $37.77 | $4.94 |
Technical Indicators
Market Signals| Indicator | TCMD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 46.60 |
| Support Level | $25.34 | $1.60 |
| Resistance Level | $30.74 | $2.26 |
| Average True Range (ATR) | 1.36 | 0.16 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 32.50 | 46.28 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.